+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating whether continuing cetuximab treatment beyond first-line progression can improve outcomes in adults with metastatic colorectal cancer who have tumors that are RAS and BRAF wild-type. This Phase 3 clinical trial aims to compare chemotherapy combined with cetuximab versus chemotherapy combined with bevacizumab, focusing on tumor response, progression-free survival, overall survival, and safety. The study builds on prior trials suggesting potential benefits of cetuximab continuation in this patient group. Participants will be randomly assigned to receive either FOLFOX or FOLFIRI chemotherapy combined with cetuximab experimental group or bevacizumab control group. Treatments are given every two weeks, with cetuximab administered as a 120-minute intravenous infusion at 500 mgm and bevacizumab at 5 mgkg. Therapy continues until disease progression, unacceptable side effects, or patient withdrawal. Tumor response will be assessed by independent review using RECIST criteria. During the study, patients undergo regular CT or MRI scans, laboratory tests, and clinical evaluations. Biological samples such as tumor tissue, blood, and stool are collected for research on resistance mechanisms and the gut microbiome. The primary measure is the overall response rate assessed up to 48 months, with secondary outcomes including overall survival, progression-free survival, and safety monitored throughout treatment and up to 30 days after the last dose. Participation lasts through treatment and follow-up periods up to several years.

Age: 18Years +All GendersPhase 3
41 locations
R

Actively Recruiting

Researchers are evaluating two treatment options for patients with metastatic colorectal cancer whose disease has worsened after standard therapies. This phase II, open-label, multicenter clinical trial compares a rechallenge treatment using irinotecan plus cetuximab to the current standard of care, trifluridinetipiracil plus bevacizumab, as third-line therapy. Patients are selected based on specific molecular features of their cancer identified through circulating tumor DNA analysis from a blood sample. The main goal is to see if the rechallenge treatment results in a higher tumor response rate compared with the standard therapy. Participants are randomly assigned to one of two groups. The experimental group receives cetuximab combined with irinotecan administered every two weeks. The control group receives oral trifluridinetipiracil on a cycle of 28 days along with bevacizumab every two weeks. Treatment continues until the disease worsens, side effects become unacceptable, or the participant chooses to stop. Tumor response is regularly checked using CT or MRI scans following RECIST criteria. After disease progression, switching to the other treatment may be considered. During the trial, participants undergo scheduled tumor assessments, safety and tolerability monitoring, and quality of life questionnaires. Adverse events are tracked from the first dose until 30 days after the last dose. The study measures objective response rate primarily, as well as progression-free survival, overall survival, treatment exposure, and quality of life over up to 36 months. Long-term follow-up will assess survival outcomes, with treatments given under medical supervision until progression or withdrawal.

Age: 18Years +All GendersPhase 2
26 locations